TESAMORELIN
Tesamorelin is a growth hormone-releasing factor analog with an FDA-approved use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That makes it unusually evidence-rich within the peptide conversation. It also creates a critical distinction: evidence for a specific approved population and outcome does not automatically validate generalized fat-loss, muscle-building or longevity claims.
Tesamorelin stimulates your body’s own growth-hormone pathway and has been shown in humans to reduce visceral abdominal fat in a specific clinical population.
Specific indication.
FDA approved since 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label explicitly says it is not indicated for weight-loss management.
A different kind of peptide story.
Tesamorelin is a synthetic analog of growth hormone-releasing factor that stimulates the pituitary to increase endogenous growth hormone secretion.
Rather than supplying growth hormone directly, tesamorelin works upstream through the growth-hormone axis. Its clinical development focused on excess visceral abdominal fat associated with HIV lipodystrophy, a specific metabolic complication seen in some adults living with HIV.
This is what strong peptide evidence looks like.
A pivotal randomized study involving 412 adults with HIV and abdominal fat accumulation found that visceral adipose tissue fell 15.2% over 26 weeks with tesamorelin while increasing 5.0% with placebo. A separate 12-month randomized study of 404 participants reported a 10.9% reduction in visceral adipose tissue versus 0.6% with placebo at six months; participants continuing tesamorelin maintained and extended the reduction, while improvements were rapidly lost after switching to placebo.
A later randomized clinical trial in 50 antiretroviral-treated adults also found significant reductions in visceral adipose tissue and a modest reduction in liver fat over six months.
Approved does not mean approved for everything.
The Gap depends on the question.
Strong crossover interest
Biohacking and performance conversations commonly reposition tesamorelin around visceral-fat reduction, body composition, GH-axis optimization, recovery and muscle-related goals.
- Frequent “belly fat” framing
- Interest in pairing with other GH-axis compounds
- Longevity/body-composition positioning
- Approved indication is often omitted from online discussion
Strong—but specific
Multiple randomized controlled studies and FDA approval support reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
- Large randomized Phase 3 evidence base
- Documented visceral-fat reduction
- Defined safety monitoring in labeling
- Evidence outside the approved population is much less definitive
Approved indication: narrow—the clinical evidence and regulatory status align. General fat loss, muscle gain and longevity optimization: wider. The same molecule can have strong evidence for one use and weak evidence for another.
What people are actually reporting.
Recurring community-use patterns are visible around Tesamorelin. We document those patterns here without turning them into a clinical recommendation.
Biohacking discussions commonly cluster around 1–2 mg per day, often at night, with some users taking it five days per week rather than daily. The approved product has its own formulation-specific labeled dose.
Tesamorelin is different from most peptides in this section because an FDA-approved dosing regimen exists for a specific indication. Current EGRIFTA SV labeling specifies 1.4 mg subcutaneously once daily for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That labeled regimen should not be conflated with off-label community protocols.
Approval gives us more answers—not all of them.
Tesamorelin has a defined prescribing-information safety framework, which is very different from compounds with little or no controlled human exposure.
Current U.S. labeling includes contraindications involving active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis. It warns about elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions and injection-site reactions. Long-term cardiovascular safety has not been established.
An established therapy that keeps evolving.
Regulatory
Newer EGRIFTA formulations keep the approved tesamorelin story current.
Current DailyMed labeling lists both EGRIFTA SV and EGRIFTA WR, while preserving the same core indication: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
Research
A randomized study expanded interest from visceral fat to liver fat.
In 50 antiretroviral-treated adults with abdominal fat accumulation, tesamorelin reduced visceral adipose tissue and produced a modest reduction in liver fat over six months. That finding generated broader metabolic interest without changing the approved indication.
Regulatory
Tesamorelin entered a different evidence category.
Initial U.S. approval established tesamorelin as an FDA-approved therapy for a defined indication rather than simply an investigational peptide.
Show the receipts.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| NEJM trial · PMID 18057338 | Randomized, placebo-controlled · n=412 | Demonstrated substantial reduction in visceral adipose tissue over 26 weeks in adults with HIV and abdominal fat accumulation. | Does not establish generalized weight-loss or anti-aging efficacy. |
| 12-month trial · PMID 20101189 | Randomized placebo-controlled + extension · n=404 | Confirmed visceral-fat reduction and showed that gains were lost after discontinuation. | Does not establish benefit in healthy body-composition populations. |
| JAMA trial · PMID 25038357 | Randomized, double-blind, placebo-controlled · n=50 | Found reductions in visceral fat and modest liver-fat reduction over six months. | Preliminary liver-fat finding does not broaden the FDA-approved indication. |
| EGRIFTA labeling | FDA-approved prescribing information | Defines indication, limitations, contraindications, warnings and monitoring framework. | Approval for one indication does not validate unrelated off-label claims. |
Read deeper.
Follow the evidence.
Metabolic Health
Explore how visceral fat, glucose regulation and body composition connect across the evidence landscape.
Retatrutide
Compare an approved, indication-specific therapy with an investigational metabolic drug producing major weight-loss signals in Phase 3.
Community Pulse
Track how approved medicines acquire entirely new identities once they enter optimization culture.
Evidence changes with the claim.
See why an FDA approval does not make every use of a molecule equally evidence-based.
What the approval actually supports.
FDA approval applies to specific populations and outcomes—not every biohacking claim.
Approved indication: EGRIFTA WR (tesamorelin) is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The product label explicitly states it is not indicated for weight-loss management and has a weight-neutral effect.
Evidence boundary: Randomized clinical evidence for visceral adipose tissue reduction in the indicated population does not prove generalized fat loss, muscle growth, better sleep or longevity benefits in otherwise healthy adults.
Safety and formulations: The label warns about elevated IGF-1, fluid retention, joint symptoms including carpal tunnel syndrome, and glucose intolerance or diabetes. EGRIFTA WR and EGRIFTA SV have different dosing instructions and are not interchangeable.
This is an editorial evidence check, not prescribing guidance. Consult current product labeling for complete safety information.